Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cytochrome b reductase 1 (CYBRD1) is a plasma membrane-associated reductase enzyme, highly expressed on the brush border membrane of duodenal enterocytes in humans. It catalyzes the ascorbate-dependent reduction of ferric (Fe3+) to ferrous (Fe2+) iron, a critical biochemical step for dietary iron absorption. CYBRD1 is a member of the cytochrome b(561) family and is regulated by iron status and hypoxia, mediated by the HIF2 transcription factor. While most studied in intestinal iron metabolism, CYBRD1 is also expressed in other tissues such as lungs, erythrocytes, and breast tissue, where it may contribute to ascorbate metabolism and extracellular oxidoreductase processes. Genetic variation in CYBRD1 influences iron status and may relate to disease states including iron overload syndromes and cancer prognosis.
For hypothetical small molecule or biologic targeting, possible mechanisms include: - Inhibition or modulation of ferric reductase activity to alter iron uptake - Modulation of expression for indirect impact on iron absorption
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cytochrome b reductase 1 (CYBRD1).